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Background: Lung cancer in nonsmokers tends to be driven by a single somatic mutation or a gene fusion. KIF5B-RET
fusion is an oncogene identified in non-small cell lung cancers. In this study, we verified the oncogenic activity of
KIF5B-RET fusion and investigated how KIF5B-RET activates the specific signaling pathways for cellular transformation.
We aimed to provide a basis for the further development of the therapy for KIF5B-RET positive lung cancer patients.
Methods: RT-PCR was used to screen for KIF5B-RET fusions in Chinese lung cancer patients. To verify the oncogenic
activity of KIF5B-RET kinase in lung cancer cells, we manipulated its expression genetically followed by colony formation
and tumor formation assays. The mechanism by which KIF5B-RET kinase induces proliferation was investigated by
western blot, coimmunoprecipitation, and administration of RET, MAPK and STAT3 inhibitors.
Results: Our study identified a KIF5B-RET fusion in Chinese NSCLC patients and demonstrated that KIF5B-RET
transfected cells showed a significantly increased proliferation rate and colony-forming ability. Furthermore, we found
that KIF5B-RET fusion kinase induced multilevel activation of STAT3 at both Tyr705 and Ser727, and KIF5B-RET-STAT3
signaling related inhibitors repressed the proliferation and tumorigenicity of lung cancer cells significantly.
Conclusions: Our data suggest that KIF5B-RET promotes the cell growth and tumorigenicity of non-small cell lung
cancers through multilevel activation of STAT3 signaling, providing possible strategies for the treatment of KIF5B-RET
positive lung cancers.
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Lung cancer is a common malignancy and is the leading
cause of cancer deaths in the world, and non-small cell
lung cancer (NSCLC) is the most common tumor type [1].
NSCLC in nonsmokers tends to be driven by a single som-
atic mutation or a gene fusion [2], such as mutated epider-
mal growth factor receptor (EGFR) [3], v-Ki-ras2 Kirsten
rat sarcoma viral oncogene homolog (KRAS) [4], the ech-
inoderm microtubule associated protein like 4 (EML4)
and anaplastic lymphoma receptor tyrosine kinase (ALK)
genes (EML4-ALK) [5], etc. These have been proven to be
“driver” genes in some subgroups of lung cancers. Re-
cently, NSCLCs were reported to harbor novel gene fu-
sions involving ROS1 [6] and RET [7,8]. RET is the* Correspondence: kaiw@zju.edu.cn
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unless otherwise stated.receptor for members of the glial cell line-derived neuro-
trophic factor family (GDNF) [9,10]. The RET gene is lo-
cated on chromosome 10 and encodes a receptor tyrosine
kinase, and the oncogenic potential of this gene product
has been suggested in several tumors, especially in thyroid
cancers [11].
KIF5B-RET is a novel fusion gene of the kinesin family
member 5B gene (KIF5B) and the rearranged during
transfection gene (RET) resulting from the chromosome
inversion inv (10) (p11; q11). It was first identified in non-
smoking Korean man as adenocarcinoma by whole-
genome and transcriptome sequencing [7]. KIF5B-RET is
reported in a low percentage of lung cancers and is more
frequent in non-smokers, in patients with adenocarcin-
oma, and exists exclusively with other mutations, such as
EGFR, Kras, Braf, ErbB2 or EML4/ALK fusions [8,12,13].
It has been demonstrated that KIF5B-RET fusions may be
oncogenic drivers and potential targets for existing small-d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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unclear how KIF5B-RET activates the specific signaling
pathways for cellular transformation. The incomplete un-
derstanding of its carcinogenic mechanisms leads to diffi-
culties in selecting targeted treatment.
Signal transducer and activator of transcription-3
(STAT3) is a member of a gene transcription protein fam-
ily that mediates a variety of biological processes including
cell proliferation and carcinogenesis [14]. Constitutive
STAT3 activation has been found in multiple types of tu-
mors [15-18]. Conventional STAT3 activation mainly con-
sists of phosphorylation on a single tyrosine residue Tyr705
resulting in dimerization of the STAT1/3 transcription fac-
tors, translocation into the nucleus and transcriptional ac-
tivation of target genes [19].
Previous studies have demonstrated that STAT3 is re-
quired for efficient cellular transformation by an array of
well-characterized oncogenes including EGFR [20], RAS
[21], ALK [22], and even RET related oncogenes such as
RET-MEN2A/2B [23], RET-FMTC [24] and RET/PTC
[25,26]. Phosphorylation on the Ser727 residue enhances
the transcriptional activity of STAT3. Different cellular
systems may affect STAT3 Tyr705 or Ser727 phosphoryl-
ation as different protein kinases may be implicated. It is
reported that RET-MEN2A mutant RETC634R induces
both Tyr705 and Ser727 phosphorylation of STAT3 for cel-
lular transformation in a process independent of JAKs and
Src [23]. By contrast, the FMTC-associated mutants
RETY791F and RETS891A implicate Src and JAKs in con-
stitutive activation of STAT3 only in Tyr705 [27]. While
thyroid-specific rearrangement of RET/PTC phosphorylat-
ing STAT3 Tyr705 requires the intrinsic kinase activity of
RET/PTC and JAKs, and c-Src kinase are not involved in
the RET/PTC-mediated activation of STAT3 [28].
Here, we screened for known KIF5B-RET fusions in
Chinese NSCLC patients using real-time polymerase chain
reaction (RT-PCR) and corroborated the oncogenic activ-
ity of this fusion kinase by colony formation and tumor
formation assays. And we explored the hypothesis that
STAT3 may be involved in the signaling triggered by
KIF5B-RET. We aimed to provide a basis for the further
development of the therapy for KIF5B-RET positive lung
cancer patients.
Results
A KIF5B-RET fusion gene is screened in Chinese
LAD patients
We performed RT-PCR assay for the KIF5B-RET fusion
genes in 100 Chinese LAD (Lung adenocarcinoma) pa-
tients. One of samples had PCR products, suspected as
KIF5B-RET fusion genes, while matched adjacent normal
lung tissue had no band, suggesting that the transloca-
tion was somatic (Additional file 1: Figure S1.A). KIF5B-
RET transcripts were detected in 1 of 100 tumors (about1.0%). None of the 7 lung cancer cell lines that we exam-
ined harbored the fusion transcript (data not shown).
From the direct sequencing of the PCR products, it
showed junctions between exon 15 of the KIF5B gene and
exon 12 of the RET gene (Additional file 1: Figure S1.B).
We subsequently measured the protein expression of
KIF5B-RET in the positive tumor tissue. Based on the
mRNA sequence of KIF5B-RET, the predicted protein is
approximately 108 kDa. Western blot analysis using an
anti-RET antibody revealed a protein band, of which the
size corresponded to the predicted value, inferring the ex-
pression of KIF5B-RET fusion protein (Figure 1A). Imuno-
histochemical analysis performed on the paraffin sections
of the positive tumor tissue revealed moderate, cytoplas-
mic, non membranal, KIF5B-RET expression in tumor
cells (Figure 1B). Since RET protein had low expression in
this sample, the staining implicated expression of the
fusion proteins.
This positive case was a poorly differentiated nodule
subtype LAD. The patient was a countrywoman aged
58 years, and had no smoking history. The mass measured
4 cm in greatest dimension, and the right lung pleura and
the bronchus were involved, but no lymph node metasta-
sis or distant metastasis (pathologic stage I b). RET ex-
pression was observed as moderately intense cytoplasmic
staining but no obvious perinuclear or paranuclear accen-
tuation. The tumor cells also had strong expression of
TTF1 and Napsin A. Characteristics are listed in Additional
file 1: Table S1 and Additional file 1: Table S2. The clinico-
pathological characteristics of this case were consistent
with previous researches [29], namely, more poorly differ-
entiated tumors, younger (<65 years), non-smokers, and
solid subtype.
KIF5B-RET fusion kinase is constitutively activated and
enhances cell proliferation
It was predicted that the N-terminal portion of the KIF5B
coiled-coil region, retained in all variants, has the ability to
dimerize through two coiled-coil structures, similar to the
KIF5B-ALK fusions [30]. Consistently, when the KIF5B-
RET variant 1 and 2 were exogenously expressed in A549
human lung cancer cells, RET Tyr905 was phosphorylated
in the absence of serum or GDNF stimulation, indicating
an aberrant activation of RET kinase by fusing with KIF5B
(Figure 2A). To determine whether KIF5B-RET directly
affects the proliferative and colony-forming abilities of
NSCLC cells, human lung cancer A549 cells were infected
with KIF5B-RET-expressing, wild type RET expressing, or
control lentivirus. After blasticidin selection, the cell pro-
liferation was measured with cell counting and the num-
ber of colonies was scored. The KIF5B-RET transfected
cells showed a significantly increasing proliferation rate
when compared with the RET transfected or control cells
(Figure 2B). Similarly, compared with control and RET-
AB
Figure 1 KIF5B-RET fusion gene is identified in a Chinese LAD patient. A. Expression of the KIF5B-RET fusion protein is shown in the positive
tumor sample. Western blot analysis showed an approximately 108 kDa but not 170 kDa (the RET protein) band. B. Immunohistochemical analysis
of KIF5B-RET expression in the positive tumor tissue. The tumor cells were arranged in solid nests and revealed moderate cytoplasmic expression
of KIF5B-RET fusion protein.
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A549 cells also caused an increase in colony number and
size (Figure 2C). Consistent with in vitro observations, we
also confirmed that the enforced expression of KIF5B-
RET caused a significant increase in A549 xenograft tumor
weight in nude mice compared with control (KIF5B-RET
group vs control group: 0.53 ± 0.2 g vs 0.22 ± 0.15 g, ***P <
0.001; Figure 3). All of these findings corroborate that the
KIF5B-RET fusion kinase promotes the growth of lung
cancer cells both in vitro and in vivo.
Signaling pathways involved in the proliferation of
KIF5B-RET positive cells
It has been shown that KIF5B-RET fusion kinase pro-
motes cell proliferation of lung cancer, then the phos-
phorylation levels of proliferation related signaling
molecules was investigated by measuring the enforced
expression of KIF5B-RET in A549 and Beas-2b cells. We
found that ERK and STAT3 signaling pathways were ab-
errantly activated in enhanced KIF5B-RET-expressing
Beas-2b (Figure 4A) or A549 cells (Figure 4B). Moreover,
the KIF5B-RET-induced phosphorylation of ERK and
STAT3 was also reduced by ZD6474 treatment in a simi-
lar dose response to RET phosphorylation (Figures 4C&4D). Taken together, ERK and STAT3 signaling pathways
may be involved in mediating the effect of KIF5B-RET
in promoting cell proliferation.
KIF5B-RET activates STAT3 both Tyr705 and Ser727 at
different levels in positive cells
To further investigate the role of STAT3 in mediating the
function of KIF5B-RET in cell growth, we analyzed STAT3
phosphorylation in 293 T cells expressing KIF5B-RET. As
shown in Figure 5A, the expression of KIF5B-RET fusion
kinase increased STAT3 phosphorylation on both Tyr705
and Ser727. As the JAK and c-Src tyrosine kinases are well
known as upstream kinases for the phosphorylation of the
Tyr705 residue in STAT3, we next asked whether these ki-
nases were still involved in KIF5B-RET-induced Tyr705
phosphorylation of STAT3. Indeed, both a JAK2 inhibitor
(AG490) and a c-Src inhibitor (PP1) inhibited STAT3 on
Tyr705 phosphorylation in various degrees. However, more
interestingly, after treating with AG490 or PP1, the
KIF5B-RET-expressing A549 cells still expressed a higher
level of STAT3 Tyr705 phosphorylation compared to the
control (Figure 5B), indicating that apart from the up-
stream JAK and c-Src kinases, KIF5B-RET may also dir-
ectly phosphorylate and activate STAT3 Tyr705. We next
CBA
Figure 2 KIF5B-RET fusion kinase is constitutively active and enhances cell proliferation in vitro. A. KIF5B-RET fusion kinase is constitutively
active. A549 lung cancer cells were transfected with an empty vector, wild-type RET (RET) or KIF5B-RET variants1 or 2 expression plasmids, and
cultured without GDNF for 48 hour. The level of phosphorylated Tyr905 (pTyr905) RET in cell lysates was analyzed by western blots. B. Expression
of KIF5B-RET fusion protein enhances positive cell proliferation in vitro. A549 cells carrying KIF5B-RET,RET or empty vector were seeded in 6-well plates
and cultured for 7 days, and cell numbers were obtained at the indicated time (*P < 0.05, **P < 0.01, Student’s t test). C. Expression of KIF5B-RET fusion
protein enhances the colony forming ability of positive cells in vitro. A549 cells carrying KIF5B-RET, RET or empty vector were seeded in 6-well plates,
and cultured for 14 days. The total number of colonies, each containing more than 40 cells, were determined (*P < 0.05, **P < 0.01, Student’s t test).
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whether KIF5B-RET binds to STAT3. KIF5B-RET-FLAG
expressing 293 T cell lysates were incubated with FLAG
antibody, and the immunecomplexes were then purified,
separated by SDS-PAGE, and analyzed with western blot.
We found that STAT3 was present in the protein complex
immunoprecipitated by the FLAG antibody (Figure 5C).
To determine whether STAT3 is the direct substrate of
KIF5B-RET, purified GST-STAT3 protein was incubated
with purified activated KIF5B-RET protein from immuno-
precipitation, and the result showed that activated KIF5B-
RET phosphorylated STAT3 at Tyr705 site (Figure 5D).
Taken together, these observations suggested that STAT3
is likely a direct substrate of KIF5B-RET in positive
NSCLC cells, and that KIF5B-RET induced cell prolifera-
tion may be mediated, at least in part, through its phos-
phorylation of STAT3 Tyr705 directly. In addition, our
previous experiments show KIF5B-RET co-activated ERK
and STAT3 signaling pathways in positive cells, and the
MEK1/2 inhibitor (U0126) attenuated the KIF5B-RET-
induced ERK1/2 and STAT3 Ser
727 phosphorylation, but
not Tyr705 phosphorylation (Figure 5E), suggesting that
KIF5B-RET-induced STAT3 Ser727 phosphorylation was
partly mediated through the Ras/Raf/MEK1/2/ERK1/2 path-
way. Since cyclinD,VEGF,and ICAM-1 are major targets ofSTAT3, and are involved in cell proliferation and invasion,
we analyzed whether KIF5B-RET affected expression of
these genes. As shown in Figure 5F, the expression of
cyclinD1, VEGF and ICAM-1 was higher in KIF5B-RET
positive cells than in parental A549 and BEAS-2B cells.
Together, KIF5B-RET fusion protein induces multilevel
activation of STAT3 which may target cyclinD1, VEGF
and ICAM-1 and play a key role in oncogenesis.
Down regulation of KIF5B-RET-STAT3 signaling
suppresses the proliferation of positive lung cancer cells
The important role of KIF5B-RET-STAT3 in promoting the
proliferation of lung cancer cells led us to wonder what
would happen after inhibition at any step of these signal-
ings. To date, a few tyrosine kinase inhibitors have been
shown to inhibit oncogenic RET activity, for example,
ZD6474, which is a selective inhibitor of the vascular endo-
thelial growth factor (VEGF) receprot-2 tyrosine kinase.
We first assessed the IC50 values of ZD6474 in four differ-
ent NSCLC cell lines (Beas-2b, NCI-H1299, A549, and
KIF5B-RET-expressing A549 cells) (Figure 6A). The IC50
value was 14.20 μM in KIF5B-RET-expressing A549 cells,
whereas in other three cell lines they were all higher than
64 μM. Western blot were then analyzed in the presence
of ZD6474, the phosphorylation of KIF5B-RET was
BA
Figure 3 Expression of KIF5B-RET fusion protein promotes the growth of positive cell xenograft tumors in vivo. A. 1 × 106 control and
enhanced KIF5B-RET expressing A549 cells were separately subcutaneously injected in the left and right flanks of mice, and the mice were shown
1 month later. B. The weight of xenograft tumors was recorded and analyzed (n = 8, **P < 0.01, Student’s t test).
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manner (Figure 6B). Consistent with these results,
ZD6474 significantly inhibited the cell proliferation
and colony formation of the KIF5B-RET-expressing
A549 cells, and it exerted less effects on the control
A549 cells (Figures 6C-6E). These findings suggest that
the suppression of the RET kinase activity reduces the
proliferation of KIF5B-RET positive cells in vitro. Since
STAT3 pathway plays an important role in mediating
the KIF5B-RET promoted cell growth, we used some
related inhibitors to investigate the effect on cell
growth after down regulation of STAT3 signaling.
U0126 is a MEK inhibitor which inhibits STAT3 Ser727
phosphorylation mediated through the Ras/Raf/MEK1/
2/ERK1/2 pathway. PP1 is an inhibitor of Src-family
tyrosine kinases which inhibits upstream kinases for
the STAT3 Tyr705 phosphorylation. S3I-201 is an in-
hibitor of STAT3 transcription factor activation,
dimerization, and gene transcription. Colony forma-
tion assays were performed in the presence or absence
of the inhibitors U0126, PP1, or S3I-201. Significantly,
all these inhibitors reduced the number and sizes of
colonies of A549 cells carrying KIF5B-RET (Figure 7A).
And the cell proliferation of A549 cells with KIF5B-
RET also markedly decreased after the treatment of the
STAT3 inhibitors S3I-201(Figure 7B).Discussion
In the era of personalized medicine, tailored treatment
based on gene alterations, including gene mutations and
gene fusions, called as “driver genes”, has become a stand-
ard practice [31]. Gene alterations encode signaling pro-
teins which are crucial for cellular proliferation and
survival, and drive tumor formation and sustain tumori-
genesis. Partial chromosomal translocation and the corre-
sponding gene fusion are not unusual among malignancies
and may serve as a driving force for carcinogenesis. Thanks
to refinements in cytogenetic techniques, an increasing
number of gene fusions are being discovered in NSCLCs,
such as ALK rearrangement and ROS1 rearrangement
[5,6]. Most recently, the RET gene rearrangement has been
identified and has been demonstrated to be a new driver
mutation in a subset of lung adenocarcinomas in some
studies [8,29]. In contrast to 13 fusion partner genes of
RET in thyroid carcinoma, only KIF5B-RET, CCDC6-RET,
TRIM33-RET and NCOA4-RET have been reported in
lung cancer, and KIF5B-RET is the most commonly identi-
fied gene fusion in NSCLCs to date [29,32].
The overall prevalence of RET fusions is 1% to 2% in
an unselected population of NSCLCs, however, this inci-
dence increases substantially to 6% in never-smokers
with lung adenocarcinomas that are pan-negative for
other known driver mutations [13]. Based on the huge
B D
A C
Figure 4 Signaling pathway of the proliferation is involved in KIF5B-RET positive cells. A & B. KIF5B-RET positively regulates the activation
of the total STATs and ERK signaling pathways in positive cells. Control and enhanced KIF5B-RET expressing BEAS-2B (A) or A549 (B) cells were
lysed and analyzed for phosphorylated Tyr705 STAT3 and Thr202/Tyr204 ERK1/2 by western blots. C & D. The suppression of KIF5B-RET kinase activity
by ZD6474 affects both STATs and ERK signaling pathways. Positive BEAS-2B or A549 cells were treated with ZD6474 at different doses for 48 h.
Cells were lysed and analyzed by western blots for indicated marker antibodies. GAPDH was used as a loading control.
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ure. The identification of RET fusion genes represent a new
addition to the growing list of actionable drivers in lung
cancers, add to the knowledge of the underlying factors be-
hind this malignancy, and more importantly, it might
change today’s therapeutic landscape in lung cancers.
It has been observed in our study that KIF5B-RET fu-
sion protein has higher levels of phosphorylation and en-
hances cell proliferation significantly. On the other hand,
in the report in Journal of Clinical Oncology, Wang et al.
[29] found that all RET-positive adenocarcinomas had a
small primary lesion but tended to present with N2 dis-
ease significantly more often than the other lung adeno-
carcinomas with small lesions (P < 0.024), which showed
KIF5B-RET positive tumor may have stronger local inva-
sion ability. The potential role of KIF5B-RET fusion genes
in lung carcinogenesis deserves further study.
The KIF5B-RET fusion protein comprises the motor do-
main and the coiled-coil domain of KIF5B, and the juxta-
membrane intracellular region of RET, including the
entire tyrosine kinase domain. Because KIF5B is expressed
ubiquitously, its active promoter may drive the expression
of KIF5B-RET. Together with dimerization through thecoiled-coil domain, the RET tyrosine kinase activity of the
fusion protein may be activated aberrantly, thus facilitating
oncogenesis in the lung. This hypothesis corroborates the
oncogenic mechanism proposed for the fusion gene
KIF5B-ALK, in which the coiled-coil domain of KIF5B is
always preserved, and its constitutive expression in lung is
believed to activate ALK and downstream oncogenic
effects [30,33].
Although information on signal transduction down-
stream of the KIF5B-RET is still limited, it has been dem-
onstrated that several tyrosine residues are phosphorylated
in RET with GDNFs stimulation, which serve as docking
sites recruits the Grb2-Gab1 and Grb2-Sos complexes that
then activate the PI3K/AKT, RAS/MAPK, p38MAPK and
c-Jun N-terminal kinase (JNK) pathways respectively, which
promote cell proliferation and survival in some endocrine
tumors [34]. In our study, KIF5B-RET fusion kinase was
shown to possess marked oncogenic activity both in vitro
and in vivo, and STAT3 signaling pathway might be the
principal downstream mediator of the oncogenesis. Strong
phosphorylation of STAT3 was presented in KIF5B-RET
positive lung cancer cells. Here we provide several lines of






Figure 5 KIF5B-RET phosphorylates and activates STAT3 at different levels in positive cell. A. KIF5B-RET phosphorylates and activates
STAT3 both Tyr705 and Ser727 in positive cells. Western blots were performed on 293 T carrying KIF5B-RET or empty vector cells lysates using the
indicated antibodies. B. JAK2 and c-Src kinase are involved in KIF5B-RET mediated-STAT3 Tyr705 phosphorylation. 293 T cells carrying KIF5B-RET
were pretreated with 15 μM AG490 (Jak2 inhibitor) or 5 μM PP1 (Src inhibitor) for the indicated times before cell lysis. Western blot was then
performed using the indicated STAT3 antibodies. C. KIF5B-RET directly interacts STAT3 in positive cells. Enhanced KIF5B-RET expressing 293 T cell
lysates were co-immunoprecipitated with control IgG or FLAG antibody. The immunoprecipitates were then subjected to western blot analysis
with the indicated antibodies. D. KIF5B-RET directly phosphorylates STAT3 Tyr705. A bacterial-expressed GST- STAT3 fusion protein was incubated
in vitro with KIF5B-RET IG that had been immunoprecipitated from 293 T carrying KIF5B-RET cell lysates. Western blots were then performed on
the reaction mixtures using the indicated STAT3 antibodies. E. KIF5B-RET also induces a Ras/ERK1/2/STAT3 Ser
727 pathway. Enhanced KIF5B-RET
expressing 293 T cells were treated overnight with U0126 (MEK inhibitor), and cell lysates were analyzed by western blot using the indicated
antibodies. F. Expression of cyclin D1, VEGF, and ICAM-1 in KIF5B-RET positive cells. Two clones of the A549 and BEAS-2B cells, which exhibited
stable KIF5B-RET expression, were analyzed cyclin D1, VEGF and ICAM-1 expression by RT-PCR, the products were separated by gel electrophoresis
and visualized using ethidium bromide staining.
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STAT3, and directly phosphorylate and activate STAT3
Tyr705. It also can mediate activation of STAT3 Tyr705 in
the JAKs/STAT3 dependent ways, and trigger Ser727 phos-
phorylation through the Ras/Raf/MEK1/2/ERK1/2 pathway.
All in all, KIF5B-RET fusion protein regulates STAT3 acti-
vation at different levels which may target cyclinD1 and
play a key role in oncogenesis.
Accumulating data shows that most tumors will depend
on more than one signaling pathway for their growth and
survival, which necessitates either the development ofmultitargeted agents or the combination of single targeted
drugs to inhibit multiple signaling pathways or multiple
steps in the same pathway [35]. In our study, different in-
hibitors were used to suppress multiple steps of the KIF5B-
RET-STAT3 pathway, such as MEK inhibitor (U0126), JAKs
or Src-family tyrosine kinases inhibitor (AG490 and PP1),
STAT3 inhibitor (S3I-201) and multi-targeted agent
(ZD6474). Significantly, all these inhibitors reduced the
cell proliferation of KIF5B-RET positive lung cancer
cells in vitro. However, the use of a combination of dif-




Figure 6 The suppression of KIF5B-RET kinase activity reduces the proliferation of positive lung cancer cells. A. Specific effects of
ZD6474 on KIF5B-RET positive cells. A549 carrying KIF5B-RET cells and negative (A549, BEAS-2B and NCI-H1299) lung cell lines were seeded in
96-well plates, and then treated at different doses as indicated for 48 hours, and analyzed the IC50 by MTT assay. B. The suppression of KIF5B-RET
kinase activity by ZD6474. The transformed KIF5B-RET A549 cells were treated either with DMSO or ZD6474, as indicated doses for 48 hours. The
level of phosphorylated Tyr905 RET was analyzed by western blot. C & D. Effect of ZD6474 on the positive cells proliferation in vitro. A549 cells
carrying KIF5B-RET or empty vector were seeded in 96-well plates and cultured for 72 hours, and proliferation rate was analyzed by MTT assay at
the indicated time, and cellular morphology was obtained by light microscope at 48 hours. E. Effect of ZD6474 on the colony-forming ability of
positive cells in vitro. A549 carrying KIF5B-RET cells were diluted and seeded in 6-well plates, treated with DMSO, ZD6474 8 μM or 16 μM for
14 days. The total number of colonies, each containing more than 40 cells, was determined (**P < 0.01, ***P < 0.001, Student’s t test).
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and clinical studies are warranted to assess the optimize
target inhibition.
Conclusions
Our results have consolidated the role of KIF5B-RET fu-
sion gene in the pathogenesis of NSCLC and identified
STAT3 as a key mediator of the transforming activity of
KIF5B-RET positive lung cancer cells. KIF5B-RET fusion
protein regulates STAT3 activation at multilevels which
may target cyclinD1 and play a key role in oncogenesis.
Our results thus provide possible strategies for the treat-
ment of KIF5B-RET positive lung cancer patients.Materials and methods
Cell lines
A549, H1299, Beas-2b, and 293 T cell lines were all from
the cell bank of Chinese academy of sciences. A549 and
H1299 cells were cultured at 37°C in RPMI-1640 supple-
mented with 10% heat-inactivated FCS. Beas-2b and
293 T cells were cultured in DMEM with 10% FCS.
Chemicals and antibodies
Different inhibitors of specific signal transduction pathways,
including Vandetanib (ZD6474), U0126, PP1, AG490 and
S3I-201, were purchased from Selleck. Phosphor-Ret
(Tyr905), Ret, phospho-STAT3 (Tyr705), Phospho-STAT3
AB C
Figure 7 Inhibition of STAT3 signaling reduces the proliferation of positive lung cancer cells. A. The inhibitors U0126, PP1 and S3I-201
reduce the colony-forming ability of KIF5B-RET positive cells. A549 cells carrying KIF5B-RET were diluted and seeded in 6-well plates, treated with
DMSO, U0126 (MEK inhibitor) 10 μM, PP1 (SRC inhibitors) 5 μM or S3I-201(STAT3 inhibitors) 100 μM for 14 days. The total numbers of colonies,
each containing more than 40 cells, were determined. (*P < 0.05, **P < 0.01, ***P < 0.001, Student’s t test). B. The suppression of STAT3 reduces the
cell proliferation of KIF5B-RET positive cells. A549 cells carrying KIF5B-RET were seeded in 96-well plates and treated with DMSO (0.3%) or S3I-201
(100 μM) for 72 hours, and were analyzed by MTT assay at the indicated time (***P < 0.001, Student’s t test). C. Strategies to inhibit KIF5B-RET in
lung cancer therapy. KIF5B-RET fusion kinase is constitutively active without GDNF stimulation. The fusion kinase induces STAT3 Tyr705 phosphorylation
directly, and also phosphorylates Tyr705 indirectly through classical JAKs /STAT3 pathway, and STAT3 transcriptional activity is further enhanced by
Ser727 phosphorylation via a MEK/ERK1/2 pathway. Inhibitors at different levels of KIF5B-RET-STAT3 signaling can suppress cell proliferation triggered by
KIF5B-RET in lung cancer cells.
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glyceraledehyde-3-phosphatedehydrogenase (GAPDH), and
anti-Flag antibodies were purchased from Cell Signaling
Technology. STAT3 recombinant protein was purchased
from Abnova.Sample collection
Primary lung cancers tissues were from Chinese patients
who did not receive neoadjuvant therapy and who under-
went resection at Zhejiang Provincial Cancer Hospital,
Hangzhou, between 2008 and 2010. The corresponding
non-neoplastic lung tissues were immediately frozen and
stored at −80°C until assayed. Informed consent and ethics
approval was obtained for research purposes. Ethics com-
mittee of the hospital approved the study.RT- PCR
Total RNA was extracted from lung cancer tissues or cul-
tured cells with TRIzol Reagent (Invotrogen). Revert Aid
First Strand cDNA Synthesis Kit (Fermentas) was used to
construct the template cDNA for realtime PCR. The primer
sequences for screening the KIF5B/RET fusion gene were
as follows: forward primer, 5′-AGGAAATGACCAACC
ACCAG-3′, and reverse primer, 5′-TCCAAATTCGCC
TTCTCCTA-3′. PCR was performed with initial denatur-
ation at 95°C for5 min, followed by 40 cycles of amplifica-
tion (at 98°C for 10 sec, 60°C for 15 sec, and 72°C for
3 min), and final extension at 72°C for 5 minutes.
Western blot
Total protein lysates were obtained from cultured cells
or tumor tissues using radio-immunoprecipitation assay.
Qian et al. Molecular Cancer 2014, 13:176 Page 10 of 11
http://www.molecular-cancer.com/content/13/1/176Cell extracts were subjected to sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (8% polyacrylamide
gels) and then transferred to nitrocellulose membranes.
The membranes were blocked overnight with TBS con-
taining 0.1% Tween 20 (TBST) and 5% nonfat milk, and
probed with the primary antibodies overnight at 4°C.
After washing with TBST, the membranes were incu-
bated with horseradish peroxidase (HRP)–conjugated
secondary antibody for 1 h at room temperature, washed
with TBST 3 times, and reacted with Super Signal West
Pico chemiluminescent substrate (Pierce).
Hematoxylin-eosin and immunohistochemical stain
Tumor samples were fixed in 10% neutral-buffered formalin
for 24 h and embedded in paraffin. For hematoxylin-eosin
stain, sections were reacted with hemalum for nuclear stain-
ing, which is followed by counterstaining with eosin for
staining of other eosinophilic structures. For immunohisto-
chemical stain, sections were reacted with primary antibodies
for 24 h at 4°C, reacted with HRP–conjugated secondary
antibody for 1 h, and diaminobenzidine (DAB) was used as
the substrate to produce an observable brown color.
Plasmids and lentiviral packaging
A full-length KIF5B-RET cDNA was cloned into lentiviral
vector for constitutive gene expression (pLenti6.3-MCS-
IRES2 vector, Invitrogen). Lentiviral vector was cotransfected
with pLP1, pLP2, and pLP/VSVG packaging vectors (Invitro-
gen) into 293 T cells. A549 and Beas-2b cells were infected
with empty, KIF5B-RET-FLAG -expressing lentiviruses, and
were treated with Blastcidin (10 μg/ml) for 2 weeks.
Colony formation assay
300 cells were cultured in a 6-well culture plate for 14 days.
At the end of incubation, cells were fixed with methanol
for 10 min and stained with crystal violet for 10 ~ 15 min.
Three wells of cell colonies were scored (≥40 cells).
Xenograft tumor model
Four-week-old athymic nude mice (BALB/c nude) were
used in these studies with the approval of the institu-
tion’s ethics committee. 1 × 106 control and A549 cells,
carrying KIF5B-RET, were separately subcutaneously
injected in the left and right flanks of mice. The tumors
were measured 1 month later. The weight of the xeno-
graft tumors was recorded and analyzed.
Co-Immunoprecipitation (Co-IP)
Flag and STAT3 antibodies were used for Co-IP. Cell ly-
sates were incubated with primary antibodies or control
IgG overnight at 4°C and the immune complex was pre-
cipitated by the ProteinG Magnetic Beads (Millipore).
The beads were then washed, boiled, and subjected to
SDS-PAGE.Statistical analysis
Values are shown as means ± SEM. Statistical analysis
was performed by Student’s t-test, and P value less than
0.05 was considered statistically significant.
Additional file
Additional file 1: Lung cancer cases screened for KIF5B-RET fusions.
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